Adjunctive carbamazepine + antipsychotics vs placebo/no adjunctive treatment + antipsychotics: Leaving the study early
- Population
- patients with schizophrenia
- Intervention
- Adjunctive carbamazepine + antipsychotics
- Comparison
- placebo/no adjunctive treatment + antipsychotics
- Outcome
- Leaving the study early
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Adjunctive carbamazepine + antipsychotics vs placebo/no adjunctive treatment + antipsychotics Acceptability of treatment Leaving the study early due to any reason · People with schizophrenia It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty). Carbamazepine for schizophrenia (2014) · Cochrane Headline outcomes only | RR 0.47 [0.16, 1.35] | 8 studies · 182 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Carbamazepine for schizophrenia 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.